×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CLRB – cellectar biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CLRB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
08:08 am
clrb
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 [Yahoo! Finance]
Low
Report
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 [Yahoo! Finance]
11/14
08:05 am
clrb
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
Low
Report
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
11/12
08:05 am
clrb
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
Low
Report
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
11/11
04:05 pm
clrb
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
Low
Report
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
11/7
06:44 am
clrb
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 [Yahoo! Finance]
Medium
Report
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 [Yahoo! Finance]
11/7
06:40 am
clrb
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
Medium
Report
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
11/1
05:00 pm
clrb
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
Low
Report
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
10/11
03:01 pm
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $14.00 price target on the stock.
Low
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $14.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
5/14/2024
06:40 am
CLRB
cellectar biosciences, inc.
MISS
Report
2.6%
cellectar biosciences, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/13
04:45 pm
clrb
Form NT 10-Q Cellectar Biosciences, For: Sep 30
Low
Report
Form NT 10-Q Cellectar Biosciences, For: Sep 30
11/1
05:16 pm
clrb
Form 8-K Cellectar Biosciences, For: Nov 01
Low
Report
Form 8-K Cellectar Biosciences, For: Nov 01
10/29
05:10 pm
clrb
Form 10-Q Cellectar Biosciences, For: Jun 30
Neutral
Report
Form 10-Q Cellectar Biosciences, For: Jun 30
10/29
05:04 pm
clrb
Form 10-Q/A Cellectar Biosciences, For: Mar 31
Neutral
Report
Form 10-Q/A Cellectar Biosciences, For: Mar 31
10/29
04:57 pm
clrb
Form 10-K/A Cellectar Biosciences, For: Dec 31
Neutral
Report
Form 10-K/A Cellectar Biosciences, For: Dec 31
8/23
05:16 pm
clrb
Form 8-K Cellectar Biosciences, For: Aug 20
Medium
Report
Form 8-K Cellectar Biosciences, For: Aug 20
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/10
Cellectar Biosciences Inc (NASDAQ: CLRB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
17.5%
12/2 Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference 15.7%
5/15 CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma 11.5%
1/9 Form 8-K Cellectar Biosciences, For: Jan 09 8.9%
5/28 Form SC 13G Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 8.8%
10/15 Form 8-K Cellectar Biosciences, For: Oct 15 8.1%
2/14 Form SC 13G/A Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 7.5%
1/3 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.75 price target on the stock. 7.0%
2/25 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.6%
12/19 Cellectar Biosciences to Present at Biotech Showcase 2020 5.9%
12/2 Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference 15.7%
5/15 CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma 11.5%
1/9 Form 8-K Cellectar Biosciences, For: Jan 09 8.9%
5/28 Form SC 13G Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 8.8%
10/15 Form 8-K Cellectar Biosciences, For: Oct 15 8.1%
2/14 Form SC 13G/A Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 7.5%
1/3 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.75 price target on the stock. 7.0%
2/25 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.6%
12/19 Cellectar Biosciences to Present at Biotech Showcase 2020 5.9%
TOP News Decliners
7/9
Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma
-26.9%
5/15 Form 8-K Cellectar Biosciences, For: May 15 -23.0%
2/19 Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study -20.9%
9/24 Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma -17.5%
11/12 Form 8-K Cellectar Biosciences, For: Nov 12 -14.7%
5/13 Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma -12.6%
2/20 Form 8-K Cellectar Biosciences, For: Feb 19 -11.9%
3/17 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%
3/9 Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update -7.9%
3/10 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
5/15 Form 8-K Cellectar Biosciences, For: May 15 -23.0%
2/19 Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study -20.9%
9/24 Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma -17.5%
11/12 Form 8-K Cellectar Biosciences, For: Nov 12 -14.7%
5/13 Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma -12.6%
2/20 Form 8-K Cellectar Biosciences, For: Feb 19 -11.9%
3/17 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%
3/9 Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update -7.9%
3/10 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: